Trial Profile

A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Paclitaxel (Primary)
Indications Head and neck cancer; Paranasal-sinus-neoplasms; Squamous cell cancer
Focus Therapeutic Use
Sponsors Fulgent Pharma

22 Apr 2026 According to Fulgent pharma release, data from the trial will be presented at the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026.
16 Mar 2026 Status changed from recruiting to active, no longer recruiting.
20 Oct 2025 According to Fulgent pharma release, data from the trial will be presented on October 20, 2025, at the European Society for Medical Oncology (ESMO), held October 17th to the 21st in Berlin, Germany.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com